Corticosteroids Interactions

Intensified electrolyte depletion, particularly hypokalemia, may occur with concurrent use of corticosteroids and chlorothiazide.

Source: NLP:chlorothiazide

Intensified electrolyte depletion, particularly hypokalemia, may occur when corticosteroids are given with chlorothiazide sodium.

Source: NLP:chlorothiazide sodium

Anticholinergic drugs in presence of increased intraocular pressure may be hazardous when taken concurrently with corticosteroids.

Source: NLP:dicyclomine hydrochloride

Expected to increase risk of immunosuppression; additive immune system effects must be considered with fingolimod coadministration.

Source: NLP:fingolimod

Intensified electrolyte depletion, particularly hypokalemia may occur.

Source: NLP:hydrochlorothiazide

Should be tapered in Crohn's disease patients on chronic corticosteroids when starting natalizumab therapy due to increased infection risk.

Source: NLP:natalizumab-sztn

Barbiturates enhance metabolism of exogenous corticosteroids. Dose adjustment may be needed when adding or withdrawing phenobarbital.

Source: NLP:phenobarbital

Avoid concomitant use due to increased risk of hypernatremia and volume overload. If unavoidable, closely monitor serum electrolytes and fluid balance.

Source: NLP:dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride

Concurrent use with sodium phosphate may result in hypernatremia.

Source: NLP:dibasic sodium phosphate, monobasic potassium phosphate and monobasic sodium phosphate

Corticosteroids produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.

Source: NLP:acarbose

Intensified electrolyte depletion, particularly hypokalemia, may occur when used concurrently with hydrochlorothiazide.

Source: NLP:amiloride hydrochloride and hydrochlorothiazide

Concurrent use may potentiate hypokalemia, which could predispose patient to cardiac dysfunction. Serum electrolytes and cardiac function should be closely monitored.

Source: NLP:amphotericin b

Corticosteroids used in triple-therapy regimens with basiliximab; no dose adjustment necessary. No increase in adverse reactions observed.

Source: NLP:basiliximab

Withdrawal of corticosteroids in chronic aspirin users may result in salicylism. Corticosteroids enhance renal clearance of salicylates.

Source: NLP:butalbital, aspirin, and caffeine

Functional antagonism exists; corticosteroids inhibit calcium absorption while calcitriol promotes it.

Source: NLP:calcitriol

Functional antagonism exists; corticosteroids inhibit calcium absorption while calcitriol promotes it. Concurrent use requires monitoring.

Source: NLP:calcitriol capsules 0.25 mcg

Corticosteroids may suppress the response to the skin test. Pharmacologic doses may suppress response after two weeks of therapy through decreased monocytes and lymphocytes, particularly T-cells.

Source: NLP:coccidioides immitis spherule-derived skin test antigen

Corticosteroid regimen is required before ELEVIDYS administration. Patients should complete vaccinations at least 4 weeks prior to corticosteroid initiation due to immunosuppressive effects.

Source: NLP:delandistrogene moxeparvovec-rokl

May produce hyperglycemia and lead to loss of glycemic control; monitor closely.

Source: NLP:empagliflozin, metformin hydrochloride

Potentiate hypokalemic effects of epinephrine.

Source: NLP:epinephrine

Potentiate the hypokalemic effects of epinephrine.

Source: NLP:epinephrine in sodium chloride

Corticosteroids may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

Source: NLP:glyburide

May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.

Source: NLP:glimepiride

Corticosteroids may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for loss of control when initiated or withdrawn.

Source: NLP:glipizide

May increase plasma ammonia levels through protein breakdown. Monitor ammonia levels closely during concomitant use.

Source: NLP:glycerol phenylbutyrate

May cause electrolyte imbalance; caution advised with haloperidol decanoate as hypokalemia, hypomagnesemia, and hypocalcemia increase QT prolongation risk.

Source: NLP:haloperidol decanoate

Concomitant usage may increase the risk of infection due to additive immune system effects.

Source: NLP:inebilizumab

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin aspart

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin aspart-szjj

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Source: NLP:insulin degludec

May decrease blood glucose lowering effect of insulin glargine; dosage increases and increased glucose monitoring may be required.

Source: NLP:insulin glargine

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin glulisine

May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin human

May decrease the blood glucose lowering effect. Dose adjustment and increased frequency of glucose monitoring may be required.

Source: NLP:insulin lispro

May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Source: NLP:insulin lispro-aabc

Caution should be exercised when using together due to potential additive effects on bone loss.

Source: NLP:isotretinoin

Increased plasma concentrations reported with concomitant administration of oral contraceptives containing ethinyl estradiol.

Source: NLP:levonorgestrel and ethinyl estradiol

Corticosteroids may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is recommended.

Source: NLP:linagliptin and metformin hydrochloride

Produce hyperglycemia and may lead to loss of glycemic control when used with metformin.

Source: NLP:metformin

May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose control.

Source: NLP:metformin er 500 mg

Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.

Source: NLP:metformin hydrochloride

May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.

Source: NLP:metformin hydrochloride extended-release tablets

May produce hyperglycemia and lead to loss of glycemic control when used with metformin.

Source: NLP:metformin hydrochloride tablet

Methohexital may influence the metabolism of corticosteroids.

Source: NLP:methohexital sodium

May increase risk of hypokalemia and increase salt and water retention.

Source: NLP:metolazone

May affect the results of the metyrapone test. Consider withdrawing if possible before testing.

Source: NLP:metyrapone

Immunosuppressant doses of corticosteroids with ocrelizumab are expected to increase the risk of immunosuppression. Consider risk of additive immune system effects when coadministering.

Source: NLP:ocrelizumab and hyaluronidase

Adjust patient's vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection. Certain vaccines are contraindicated for patients on substantially immunosuppressive steroid doses.

Source: NLP:onasemnogene abeparvovec-brve

Caution must be exercised in the administration of Sodium Chloride Injection to patients receiving corticosteroids due to potential interaction.

Source: NLP:0.9% sodium chloride

Barbiturates enhance metabolism of exogenous corticosteroids. Dosage adjustments may be needed when barbiturates are added or withdrawn.

Source: NLP:pentobarbital sodium

Barbiturates appear to enhance metabolism of exogenous corticosteroids. Patients stabilized on corticosteroid therapy may require dosage adjustments if barbiturates are added or withdrawn.

Source: NLP:phenobarbital sodium

May increase risk of hypernatremia and volume overload. Monitor serum electrolytes, fluid balance, and acid-base balance if use cannot be avoided.

Source: NLP:sodium chloride and potassium chloride

Concurrent use with sodium phosphate may result in hypernatremia.

Source: NLP:potassium phosphate, monobasic and sodium phosphate, monobasic, anhydrous

Corticosteroids decrease plasma salicylate levels; tapering doses may promote salicylism.

Source: NLP:salicylic acid 10%

May potentiate LEUKINE's myeloproliferative effects. Use with caution and monitor frequently for clinical and laboratory signs of excess myeloproliferation.

Source: NLP:sargramostim

May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.

Source: NLP:sitagliptin and metformin hydrochloride

Caution must be exercised when administering 0.45% Sodium chloride injection to patients receiving corticosteroids due to potential interaction.

Source: NLP:sodium chloride

May cause protein catabolism and potentially increase plasma ammonia levels in patients with impaired urea formation ability.

Source: NLP:sodium phenylacetate and sodium benzoate

May increase plasma ammonia level through breakdown of body protein; monitor ammonia levels closely.

Source: NLP:sodium phenylbutyrate

Somatropin may alter clearance of corticosteroids metabolized by CYP450 liver enzymes; careful monitoring is advised.

Source: NLP:somatropin

Intensified electrolyte depletion, particularly hypokalemia, may occur.

Source: NLP:spironolactone

Intensified electrolyte depletion, particularly hypokalemia, may occur.

Source: NLP:spironolactone and hydrochlorothiazide

Concurrent use with testosterone may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Source: NLP:testosterone

Concurrent use may result in increased fluid retention; use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Source: NLP:testosterone cypionate

Concurrent use may result in increased fluid retention; use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Source: NLP:testosterone enanthate

Concurrent use with testosterone may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Source: NLP:testosterone gel, 1%

Concurrent use may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Source: NLP:testosterone undecanoate

Increased risk of hypokalemia when used concomitantly with torsemide.

Source: NLP:torsemide

Concurrent use with hydrochlorothiazide may intensify electrolyte imbalance, particularly hypokalemia, though triamterene presence minimizes this effect.

Source: NLP:triamterene and hydrochlorothiazide

Corticosteroids may depress or suppress reactivity to tuberculin test; reduced reactivity may persist for 5-6 weeks after discontinuation.

Source: NLP:tuberculin purified protein derivative

Concomitant use may increase risk of infection due to additive immune system effects. Consider risk of additive immunosuppression when co-administering.

Source: NLP:ublituximab

Used concomitantly in approximately 40% of Crohn's disease and 50% of ulcerative colitis subjects. Use did not appear to influence overall safety or efficacy of ustekinumab.

Source: NLP:ustekinumab-aauz

Used concomitantly in approximately 40-50% of inflammatory bowel disease subjects; did not appear to influence overall safety or efficacy of ustekinumab.

Source: NLP:ustekinumab-hmny

Used concomitantly in ~40-50% of CD/UC subjects; did not appear to influence overall safety or efficacy of ustekinumab.

Source: NLP:ustekinumab-ttwe

No significant interactions observed with concurrent use of corticosteroids for up to 28 days in clinical trials.

Source: NLP:glatiramer acetate